急性缺血性脑卒中患者超早期基质金属蛋白酶表达与临床预后的关系被引量：14

The correlation between the ultra-early matrix metalloproteinases expression levels and the prognosis of acute ischemic stroke patients

暂未订购

导出

摘要目的研究急性缺血性脑卒中超早期基质金属蛋白酶（MMPs）表达水平同患者临床预后的关系。方法选择发病6h内完成血标本收集的急性颈内动脉系统脑梗死患者47例，分为临床结局良好组（24例）和临床结局不良组（23例）。MMPs指标包括MMP-2、MMP-9和MMP-13；90天后随访改良的Ranking量表（mRS）评分，临床结局良好定义为mRS 0-1分，临床结局不良定义为mRS 2-6分。结果临床结局良好组患者MMP-2、MMP-9和MMP-13的表达水平分别为（241.88±69.34）μg／L、（80．83±67．24）μg／L和（74．25±26．51）ng／L，临床结局不良组患者分别为（243．57士88．48）μg／L、（147．39±132．64）μg／L和（94．80±61．49）ng／L，仅MMP9在两组间的差异有统计学意义（P=0.039）。结论急性缺血性脑卒中超早期MMP-9表达水平有助于判断患者的临床预后，而MMP-2和MMP-13水平同患者临床预后无关。 Objective To evaluate the correlation between the ultra-early matrix metalloproteinases （MMPs） expression levels and the prognosis of acute ischemic stroke patients. Methods A total of 47 acute ischemic stroke patients whose blood samples collected within 6 hours after onset were studied. The patients were divided into good clinical outcome group （24 patients） and bad clinical outcome group （23 patients）. MMP-2,MMP-9 and MMP-13 were detected. All patients were followed up for three months after onset and modified Ranking scale （mRS） scores were recorded. Good clinical outcome were defined as mRS 0--1 and bad clinical outcome were defined as mRS 2-6. Results The average expression levels of MMP-2, MMP-9 and MMP-13 in good clinical outcome group were （241.88±69.34）μ/L, （80.83±67.24）μg/L and （74.25±26.51） ng/L re- spectively,while they were （243.57±88.48）μg/L,（147.39±132.64）μg/L and （94.80±61.49）ng/L respectively in bad clinical outcome group. Only MMP-9 expression was significantly differ- ent（P=0.039） between the two groups. Conclusion Ultra-early MMP-9 expression level may help to judge the prognosis of acute ischemic stroke patients, while there is no correlation between early MMP-2 and MMP-13 expression levels and prognosis.

作者张彤郑晓霞廖晓凌王伊龙赵性泉王拥军

机构地区首都医科大学附属北京天坛医院北京生物制品研究所

出处《中华老年心脑血管病杂志》 CAS 北大核心 2008年第2期109-111,共3页 Chinese Journal of Geriatric Heart,Brain and Vessel Diseases

基金首都医科大学基础-临床合作课题(2006JL39) 首都医科大学附属北京天坛医院青年基金课题(200508)

关键词脑血管意外基质金属蛋白酶预后 cerebrovascular accident matrix metalloproteinases prognosis

分类号 R743.3 [医药卫生—神经病学与精神病学]

引文网络
相关文献

参考文献9

1Paciaroni M,Caso V,Venti M,et al. Outcome in patients with stroke associated with internal carotid artery occlusion. Cerehrovasc Dis, 2005,20 : 108-113.
2Fatar M,Stroick M,Griebe M,et al, Matrix metalloproteinases in cerebrovascular diseases, Cerebrovasc Dis, 2005, 20: 141- 151.
3Cunningham LA,Wetzel M, Rosenberg GA. Multiple roles for MMPs and TIMPs in cerebral ischemia. Glia, 2005, 50: 329- 339.
4Zoppo GJ, Milner R, Mabuchi T, et al. Microglial activation and matrix protease generation during focal cerebral ischemia. Stroke, 2007,38 : 646-651.
5Asahi M,Asahi K,Jung JC,et al. Role of matrix metalloproteinase 9 after focal cerebral ischemia: effects of gene knockout and enzyme inhibition with BB 94. J Cereb Blood Flow Metab, 2000,20:1681-1689.
6Asahi M,Rammohan R, Sumii T, et al. Antiactin-targeted immunoliposomes ameliorate tissue plasminogen activator-induced hemorrhage after focal embolic stroke. J Cereb Blood Flow Metab,2003,23 : 895-899.
7Ning M,Furie KL, Koroshetz WJ,et al. Association between tPA therapy and raised early matrix metalloproteinase-9 in acute stroke. Neurology,2006,66 : 1550-1555.
8Montaner J, Rovira A, Molina CA,et al. Plasmatic level of neuroinflammatory markers predict the extent of diffusion-weighted image lesions in hyperacute stroke. J Cereb Blood Flow Metab, 2003,23: 1403-1407.
9Rosell A, Alvarez-Sabin J, Arenillas JF, et al. A matrix metalloproteinase protein array reveals a strong relation between MMP-9 and MMP-13 with diffusion-weighted image lesion increase in human stroke. Stroke, 2005,36 : 1415-1420.